Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer

Liver International

Volumn 31, Issue 10, 2011, Pages 1542-1553

  Argnani, Rafaela ^a   Marconi, Peggy ^a   Volpi, Ilaria ^a   Bolanos, Elixabet ^a   Carro, Elvira ^a   Ried, Christine ^b   Santamaria, Enrique ^a   Pourchet, Aldo ^c,d   Epstein, Alberto L ^c,d   Brocker, Thomas ^b   Corrales, Fernando Jose ^a   Manservigi, Roberto ^a   Goicoechea, Ibai ^a   Foschini, Mariagiovanna ^a   Hernandez Alcoceba, Ruben ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITÉ DE LYON   (France)

^d CNRS   (France)

Author keywords

Cancer; Herpes simplex virus; Liver; Oncolytic virus

Indexed keywords

CELL PROTEIN; ERLIN 2 PROTEIN; FORTILIN; LUCIFERASE; ONCOLYTIC HERPES VIRUS; RUVB LIKE 2 PROTEIN; SPACER DNA; TETRAMER; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CARCINOMA CELL; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY; PHENOTYPE; REPORTER GENE; SPINAL CORD; TUMOR CELL DESTRUCTION; UTERUS; VIRUS IMMUNITY; VIRUS STRAIN;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LUCIFERASES; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 80053962221     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02628.x     Document Type: Article

References (36)

1. Watanabe D. Medical application of herpes simplex virus. J Dermatol Sci 2010; 57: 75-82.
2. Harrow S, Papanastassiou V, Harland J, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004; 11: 1648-58.
3. Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 2006; 13: 975-92.
4. Bennett JJ, Delman KA, Burt BM, et al. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 2002; 9: 935-45.
5. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 1997; 71: 5124-32.
6. Nakamura H, Kasuya H, Mullen JT, et al. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 2002; 109: 871-82.
7. Jeyaretna DS, Kuroda T. Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction. Curr Opin Mol Ther 2007; 9: 447-66.
8. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-40.
9. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-71.
10. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
11. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-63.
12. Johnson PA, Best MG, Friedmann T, Parris DS. Isolation of a herpes simplex virus type 1 mutant deleted for the essential UL42 gene and characterization of its null phenotype. J Virol 1991; 65: 700-10.
13. Santamaria E, Mora MI, Carro-Roldan E, et al. Identification of replication-competent HSV-1 Cgal+ strain targets in a mouse model of human hepatocarcinoma xenograft. J Proteomics 2009; 73: 153-60.
14. Santamaria E, Mora MI, Potel C, et al. Identification of replication-competent HSV-1 Cgal+ strain signaling targets in human hepatoma cells by functional organelle proteomics. Mol Cell Proteomics 2009; 8: 805-15.
15. Tognon M, Manservigi R, Cavrini V, Campadelli-Fiume G. Characterization of a herpes simplex virus type 1 mutant resistant to benzhydrazone, a selective inhibitor of herpesvirus glycosylation. Proc Natl Acad Sci USA 1984; 81: 2440-3.
16. Sedarati F, Stevens JG. Biological basis for virulence of three strains of herpes simplex virus type 1. J Gen Virol 1987; 9: 2389-95.
17. Takakuwa H, Goshima F, Nozawa N, et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 2003; 148: 813-25.
18. Teshigahara O, Goshima F, Takao K, et al. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10. J Surg Oncol 2004; 85: 42-7.
19. Kimata H, Imai T, Kikumori T, et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol 2006; 13: 1078-84.
20. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002; 62: 2306-12.
21. Israyelyan AH, Melancon JM, Lomax LG, et al. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells. Hum Gene Ther 2007; 18: 457-73.
22. Israyelyan A, Chouljenko VN, Baghian A, David AT, Kearney MT, Kousoulas KG. Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. Virol J 2008; 5: 68.
23. Rousseau B, Menard L, Haurie V, et al. Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology 2007; 46: 1108-18.
24. Sanchez-Quiles V, Santamaria E, Segura V, Sesma L, Prieto J, Corrales FJ. Prohibitin deficiency blocks proliferation and induces apoptosis in human hepatoma cells: molecular mechanisms and functional implications. Proteomics 2010; 10: 1609-20.
25. Browman DT, Resek ME, Zajchowski LD, Robbins SM. Erlin-1 and erlin-2 are novel members of the prohibitin family of proteins that define lipid-raft-like domains of the ER. J Cell Sci 2006; 119: 3149-60.
26. Li F, Zhang D, Fujise K. Characterization of fortilin, a novel antiapoptotic protein. J Biol Chem 2001; 276: 47542-9.
27. Graidist P, Yazawa M, Tonganunt M, et al. Fortilin binds Ca2 + and blocks Ca2 + -dependent apoptosis in vivo. Biochem J 2007; 408: 181-91.
28. Takahashi Y, Karbowski M, Yamaguchi H, et al. Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Mol Cell Biol 2005; 25: 9369-82.
29. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008; 48: 83-90.
30. Hu P, Han Z, Couvillon AD, Exton JH. Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J Biol Chem 2004; 279: 49420-9.
31. Coles RM, Mueller SN, Heath WR, Carbone FR, Brooks AG. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J Immunol 2002; 168: 834-8.
32. Nomura N, Kasuya H, Watanabe I, et al. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases. Cancer Chemother Pharmacol 2009; 63: 321-30.
33. Kulu Y, Dorfman JD, Kuruppu D, et al. Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther 2009; 16: 291-7.
34. Kasuya H, Pawlik TM, Mullen JT, et al. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res 2004; 64: 2561-7.
35. Lopez C. Genetics of natural resistance to herpesvirus infections in mice. Nature 1975; 258: 152-3.
36. Kehm R, Rosen-Wolff A, Darai G. Restitution of the UL56 gene expression of HSV-1 HFEM led to restoration of virulent phenotype; deletion of the amino acids 217 to 234 of the UL56 protein abrogates the virulent phenotype. Virus Res 1996; 40: 17-31.